Boulevard Bio raises $65M to expand immunology pipeline, eyes Vera's IgAN candidate

Boulevard Bio announced it has secured $65 million in financing to broaden its immunology portfolio. The new capital will support the development of two immune‑resetting drugs the company discovered internally and a third candidate sourced from Vera, which targets IgA nephropathy.

The infusion of funds reflects a growing trend of biotech startups leveraging assets originating from China alongside in‑house discoveries. Boulevard Bio plans to integrate Vera's IgAN drug into its existing research program to accelerate clinical progress.

With the additional resources, the company aims to advance its pipeline toward later‑stage trials, positioning itself for potential partnerships or further investment as it pursues novel immunology therapies.